


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技（武漢）股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

VOLUNTARY ANNOUNCEMENT

HANX BIOPHARMACEUTICALS TO PRESENT FOUR POSTER PRESENTATIONS AT THE 2026 AACR MEETING

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “**Company**” or “**Hanx Biopharmaceuticals**”) on a voluntary basis.

The Board is pleased to announce that four innovative drug research abstracts of the Company will be presented in the form of posters at the 2026 Annual Meeting of the American Association for Cancer Research (“**AACR**”). The 2026 AACR Annual Meeting will be held at the San Diego Convention Center, California, the United States from April 17 to 22, 2026. These selected achievements further validate the Company’s research and development capabilities and innovation strength.

Details of the poster presentations are set out below:

1. POSTER PRESENTATION: HX044

HX044 is a globally innovative CTLA-4/SIRP α bifunctional fusion protein and a next-generation CTLA-4 targeted therapy. By simultaneously targeting CTLA-4 and CD47, it enhances the depletion of regulatory T-cells in the tumor microenvironment, thereby reducing tumor immunosuppression and strengthening anti-tumor activity. It is mainly developed for solid tumors resistant to PD-1/ICI therapy, forming a synergistic and complementary tumor immunology pipeline with HX009 developed by the Company.

- **Abstract Title:** Non-Clinical PK and PD Modeling to Assess the Therapeutic Window of HX044, a Novel CTLA4 x CD47 BsAb, as Comparison with Ipilimumab
- **Format:** Poster
- **Location:** Poster Section 6, Poster Board#21
- **Session Time:** 14:00–17:00, Tuesday, April 21, 2026 (PT)
- **Abstract Number:** 5549

2. POSTER PRESENTATION: HX116

HX116 is a potential first-in-class bispecific antibody-drug conjugate (“**BsAb ADC**”) independently developed by the Company, targeting PD-(L)1×VEGF. It incorporates additional mechanisms of action (such as direct tumor killing and anti-tumor immunity enhanced by immunogenic cell death) to boost anti-tumor activity and has significant market potential. In preclinical studies, HX116 demonstrated superior activity over its parental BsAb.

- **Abstract Title:** Explore a Novel Multi-Modal PD-L1xVEGF-ADCs (HX116) for Potential Enhanced Potency For Solid Tumor Treatments
- **Format:** Poster
- **Location:** Poster Section 44, Poster Board #2
- **Session Time:** 14:00–17:00, Tuesday, April 21, 2026 (PT)
- **Abstract Number:** 6536

3. POSTER PRESENTATION: HX112

HX112 is a novel PD-L1 targeted antibody-drug conjugate (“**ADC**”) independently developed by the Company, intended for the treatment of pan-solid tumors.

- **Abstract Title:** A Novel Multi-Modal PD-L1-ADC Could be a Potential Candidate Treatment for Pan-Solid Tumors with Enhanced Tumor-Specificity
- **Format:** Poster
- **Location:** Poster Section 6, Poster Board #30
- **Session Time:** 09:00–12:00, Wednesday, April 22, 2026 (PT)
- **Abstract Number:** 6949

4. **POSTER PRESENTATION: 3D TUMOR ORGANOID ADC EVALUATION SYSTEM**

This study introduces an innovative preclinical ADC evaluation platform established by the Company, validating that 3D tumor organoids are more predictive of in vivo anti-tumor efficacy than 2D cell cultures.

- **Abstract Title:** 3D-Tumor Organoid, over 2D-Cell, Is More Predictive of In Vivo Anti-Cancer Pharmacology in Assessing ADC Candidates
- **Format:** Poster
- **Location:** Poster Section 12, Poster Board #26
- **Session Time:** 09:00–12:00, Tuesday, April 21, 2026 (PT)
- **Abstract Number:** 4448

The Company will continue to advance the research and development of its innovative drug pipeline, committed to providing more effective and safer treatment options for cancer patients.

ABOUT HANX BIOPHARMACEUTICALS

Established in 2014, HanX Biopharmaceuticals (Wuhan) Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Guided by a mission and vision driven by innovation, HanX Biopharmaceuticals focuses on discovering, developing, and commercializing First-in-Class and Best-in-Class therapies for cancer and autoimmune diseases. The company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.

Warning under 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The relevant products may not ultimately be successfully developed and marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing the Company's shares.

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, 10 April 2026

As at the date of this announcement, the Company's Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Ms. Xiao Jieyu and Mr. Liu Min as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.